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Hyper-IgE syndrome (HIES) is a rare complex 
primary  immunodeficiency,  characterized  by 
atopic  dermatitis,  extremely  high  serum  IgE 
levels, staphylococcal skin abscesses, and pneu-
monia associated with disproportionately mild 
inflammatory  responses  (Grimbacher  et  al., 
2005; Minegishi, 2009). Treatments so far are 
symptomatic, including the prevention of bac-
terial and fungal infections and management of 
eczema. Previous studies suggested the bene-
fit from bone marrow transplantation, Ig re-
placement, and IFN and G-CSF administration 
(Grimbacher et al., 2005), but a general role for 
immune reconstitution and modulation in HIES 
is unproven. To improve the long-term quality 
of life of HIES patients, it is necessary to de-
velop a new treatment strategy based on a bet-
ter understanding of molecular mechanisms of 
this syndrome. We recently demonstrated that 
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Hyper-IgE syndrome (HIES) is a primary immunodeficiency characterized by recurrent 
staphylococcal infections and atopic dermatitis associated with elevated serum IgE levels. 
Although defective differentiation of IL-17–producing CD4+ T cells (Th17) partly accounts 
for the susceptibility to staphylococcal skin abscesses and pneumonia, the pathogenesis of 
atopic manifestations in HIES still remains an enigma. In this study, we examined the 
differentiation and function of Th1, Th2, regulatory T cells (Treg cells), and dendritic cells 
(DCs) in HIES patients carrying either STAT3 or TYK2 mutations. Although the in vitro 
differentiation of Th1 and Th2 cells and the number and function of Treg cells in the pe-
ripheral blood were normal in HIES patients with STAT3 mutations, primary and monocyte-
derived DCs showed defective responses to IL-10 and thus failed to become tolerogenic. 
When treated with IL-10, patient DCs showed impaired up-regulation of inhibitory mol-
ecules on their surface, including PD-L1 and ILT-4, compared with control DCs. Moreover, 
IL-10–treated DCs from patients displayed impaired ability to induce the differentiation of 
naive CD4+ T cells to FOXP3+ induced Treg cells (iTreg cells). These results suggest that the 
defective generation of IL-10–induced tolerogenic DCs and iTreg cells may contribute to 
inflammatory changes in HIES.
© 2011 Saito et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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X-linked  (IPEX)  syndrome  (Bennett  et  al.,  2001; Wildin   
et al., 2001). Patients with IPEX syndrome suffer from enter-
opathy, autoimmune diabetes and thyroiditis, food allergy,   
and atopic dermatitis with extremely high serum IgE levels. 
FOXP3 deficiency in mice also leads to atopic manifestations 
(Fontenot et al., 2003; Lin et al., 2005).
DCs  are  central  to  the  orchestration  of  the  various 
types of immunity and tolerance (Banchereau et al., 2000;   
Kapsenberg, 2003; Steinman et al., 2003). Immature DCs 
function as sentinels in the periphery, undergoing terminal 
differentiation in response to various danger signals. Maturing 
DCs migrate to the lymph nodes, where they acquire potent 
antigen-presenting capacity and induce vigorous T cell re-
sponses by expressing co-stimulatory molecules and secreting 
large amounts of proinflammatory cytokines. The interaction 
between DCs and naive CD4+ T cells is considered to de-
termine the fate of CD4+ T cells. Cytokines produced by 
DCs, such as IL-12 and IFN-, may bias CD4+ T cell priming 
toward the Th1 pathway (Schulz et al., 2000). Notch ligands, 
such as Jagged 1, expressed by DCs may promote CD4+  
T cells toward the Th2 pathway (Amsen et al., 2009). In addi-
tion, DCs play a key role in the induction and maintenance   
of peripheral T cell tolerance (Steinman et al., 2003; Rutella 
et al., 2006).
We investigated the molecular mechanism underlying the 
atopic manifestations in HIES by studying Th1–Th2–Treg cell 
balance and the development and function of primary and 
monocyte-derived DCs (MoDCs). The results suggest that 
IL-10 signaling by DCs may be crucial for the generation of 
tolerogenic DCs and iTreg cells for the maintenance of an   
appropriate Th1–Th2–Treg cell balance in vivo in humans.
RESULTS
Normal Th1 and Th2 differentiation from naive CD4+ T cells 
but increased Th2 cytokine production from activated  
T cells in PBMCs of STAT3 patients
We first evaluated Th1 and Th2 cell development of naive 
CD4+ T cells in STAT3 patients. Naive CD4+ T cells were 
unstimulated or stimulated with anti-CD3 and anti-CD28 
(anti-CD3/CD28) mAbs under neutral, Th1, and Th2 differ-
entiation conditions, and the development of IFN-– and 
IL-4–producing cells was evaluated by cytoplasmic staining 
and flow cytometry. The development of Th1 and Th2 cells 
was similar in control subjects and STAT3 patients (Fig. S1 A). 
This observation was confirmed by ELISA of the culture   
supernatants of naive CD4+ T cells, showing similar levels of 
IFN-, IL-5, and IL-13 secretion for control subjects and 
STAT3 patients (Fig. S1 B). We next evaluated Th1 and Th2 
cytokine  production  from  PBMCs  after  stimulation  with 
anti-CD3/CD28 mAbs. The production of IFN- was equiv-
alent between control subjects and STAT3 patients, but the 
production of IL-5 and IL-13 was increased in STAT3 pa-
tients compared with control subjects (Fig. S1 C). These re-
sults suggest that cells in PBMCs other than naive CD4+  
T cells are likely to be responsible for increased Th2 cytokine 
production in STAT3 patients.
most cases of HIES are caused by dominant-negative (DN) 
mutations of the STAT3 gene (Holland et al., 2007; Minegishi   
et al., 2007). However, the pathogenesis of this syndrome   
remains unclear. In particular, the molecular mechanisms   
underlying the allergic manifestations, including atopic der-
matitis and extremely high serum IgE levels, remain one of 
the great enigmas in the pathogenesis of this syndrome.
STAT3 is a transcription factor that binds to the promoter 
regions of various genes, including those encoding acute-
phase proteins. STAT3 plays a critical role in signal transduc-
tion for many cytokines, including those of the c family 
(IL-2, IL-7, IL-9, IL-15, and IL-21), the gp130 family (IL-6, 
IL-11, IL-27, and IL-31), the IL-10 family (IL-10 and IL-22), 
and receptor-type tyrosine kinases. The systemic deletion of 
STAT3 in mice is lethal, but studies involving the tissue- 
specific deletion of STAT3 have demonstrated that STAT3 
plays a critical role in cell migration, survival, proliferation, 
apoptosis, inflammation, and tumorigenesis in many tissues 
(Akira, 2000). Furthermore, recent data unanimously demon-
strated that STAT3 plays an essential role for Th17 cell devel-
opment in humans (de Beaucoudrey et al., 2008; Ma et al., 
2008; Milner et al., 2008; Renner et al., 2008; Minegishi et al., 
2009), which could explain, at least in part, why HIES patients 
suffer from recurrent staphylococcal infections confined to 
the skin and lung (Minegishi et al., 2009).
Allergic diseases may result from an inappropriate balance 
between effector Th2 cells and Treg cells (Umetsu and DeKruyff, 
2006; Akdis and Akdis, 2009; Lloyd and Hawrylowicz, 2009). 
Th2 cells respond to allergens and produce IL-4, IL-5, IL-9, 
and IL-13. Th2 cytokines induce changes in blood vessels that 
lead to the up-regulation of intercellular adhesion molecule 1 
and vascular cell-adhesion molecule 1, in turn leading to the 
recruitment of very late antigen 4–expressing eosinophils. These 
factors also induce the survival and activation of eosino-
phils. In addition, IL-4 and IL-13 are responsible for pro-
moting Ig class switching to IgE (Hammad and Lambrecht, 
2008). Newly identified cytokines such as IL-25, IL-31, and 
IL-33  also  participate  in Th2  cell–mediated  inflammation 
(Dillon et al., 2004; Wang et al., 2007; Kakkar and Lee, 2008). 
Th1 cells may also contribute to allergic inflammation by in-
ducing the apoptosis of epithelial cells in atopic dermatitis 
(Trautmann et al., 2000).
Treg cells are key mediators of peripheral tolerance that 
actively suppress effector T cells and inhibit immune response–
mediated tissue damage. Both FOXP3+ Treg cells and IL-10–
producing FOXP3 Treg cells play an essential role in the 
regulation of allergic inflammation (Curotto de Lafaille et al., 
2001; Zheng and Rudensky, 2007; Sakaguchi et al., 2008). 
There are two types of FOXP3+ Treg cells: natural Treg cells 
(nTreg cells) and induced Treg cells (iTreg cells). nTreg cells de-
velop in the thymus, whereas iTreg cells develop in the periph-
ery. In the presence of TGF-1, naive FOXP3 CD4+ T cells 
are converted into FOXP3+ iTreg cells (Chen et al., 2003; 
Coombes et al., 2007; Rubtsov and Rudensky, 2007; Zheng 
et al., 2007). Mutations in the human FOXP3 gene result   
in immune dysregulation, polyendocrinopathy, enteropathy, JEM VOL. 208, February 14, 2011 
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of 1.25 × 103 control Treg cells to the 1.25 × 104 control re-
sponder T cells resulted in levels of [3H]thymidine incorpora-
tion 55% lower than those obtained after the addition of   
1.25 × 103 control responder T cells. Levels of [3H]thymidine 
incorporation were similarly lowered by the addition of   
1.25 × 103 patient Treg cells to the 1.25 × 104 patient responder   
T cells (Fig. 1 B). Modification of the ratio of Treg cells to re-
sponder T cells from 1:1 (Treg cell/responder T cell) to 1:100 
resulted in no significant difference in the percent suppression 
of [3H]thymidine incorporation between control subjects and 
STAT3 patients (Fig. 1 C). These results indicate that the   
in vivo generation and ex vivo function of Treg cells were 
normal in STAT3 patients.
Defective IL-10 signaling in MoDCs from STAT3 patients
We next evaluated the generation of MoDCs in vitro. Isolated 
CD14+ monocytes from the PBMCs of control subjects and 
STAT3 patients were cultured with GM-CSF and IL-4 for   
5 d and then allowed to mature in the presence of LPS for   
2 d. MoDC differentiation was normal, as shown by evalua-
tions of the forward and side light scatter of the cells 
(Fig. S2 A), the expression levels of CD1a (Fig. S2 B), 
CD80, CD83, and CD86 (Fig. S2 C), and FITC-
dextran uptake (Fig. S2 D). Of note, levels of 
CD86  expression  before  LPS  stimulation  were 
slightly higher in STAT3 patients than in control 
subjects (Fig. S2 C), suggesting that autocrine IL-10 
may regulate the expression of DC maturation mark-
ers in control subjects but not in STAT3 patients 
(Corinti et al., 2001).
We have previously demonstrated that STAT3 
plays an important role in IL-10 signal transduc-
tion  in  human  monocyte-derived  macrophages 
(Minegishi et al., 2007). We therefore investigated 
IL-10 signal transduction in MoDCs. Consistent 
with our previous findings, the transcriptional   
The number and suppressive activity of Treg cells  
in the peripheral blood are normal in STAT3 patients
We next evaluated the number of FOXP3+ Treg cells among 
PBMCs because STAT3 is involved in the transduction of 
IL-6 and IL-21 signals, which may influence the balance be-
tween nTreg cell and Th17 cell differentiation (Harrington   
et  al.,  2005;  Bettelli  et  al.,  2006;  Ivanov  et  al.,  2006;   
Veldhoen et al., 2006). Similar numbers of PBMCs were ob-
tained from control subjects and STAT3 patients, and these 
cells were stained for extracellular CD4 and CD25 and intra-
cellular FOXP3 and evaluated by flow cytometry. The per-
centages of CD4+CD25+ cells and CD4+FOXP3+ cells did 
not differ significantly between control subjects and STAT3 
patients (Fig. 1 A).
We then investigated the function of Treg cells in the pe-
ripheral blood ex vivo. CD4+CD25+CD62L+ Treg cells were 
obtained from the peripheral blood of control subjects and 
STAT3 patients at a purity of >99% and were co-cultured 
with autologous CD4+CD25CD62L+ responder T cells in the 
presence or absence of anti-CD3/CD28 mAbs. The addition 
Figure 1.  The number and suppressive activity of  
Treg cells in the peripheral blood are normal in STAT3 
patients. (A, left) Representative dot plots gated on CD4+ 
peripheral blood T cells from a control subject and a STAT3 
patient. (right) Summary data from eight control subjects 
and eight STAT3 patients showing percentages of 
CD4+FOXP3+ cells. Data are representative of at least two 
independent experiments. (B) CD4+CD25CD62L+ responder 
T cells and CD4+CD25+CD62L+ Treg cells were isolated by cell 
sorting. Responder T cells and Treg cells were co-cultured as 
indicated for 5 d with or without a 1:100 (vol/vol) dilution  
of anti-CD3 + anti-CD28 mAb–coated beads. For the evalua-
tion of proliferation, 1 µCi (37 kBq) [3H]thymidine was  
added to the culture medium for the last 18 h. Graph shows 
mean ± SD. (C) CD4+CD25CD62L+ responder T cells and 
CD4+CD25+CD62L+ Treg cells were isolated and cultured as in B at  
the indicated ratio. Summary data (n = 8 each) are shown. 
Data are representative of at least two independent experi-
ments performed in triplicate. (A and C) Horizontal bars  
indicate mean values.238 Impaired iTreg cell genesis in hyper-IgE syndrome | Saito et al.
control subjects. FOXP3 messenger RNA (mRNA) levels in 
CD4+ T cells co-cultured with control IL-10–DCs were ap-
proximately four times higher than those for cells co-cultured 
with untreated control MoDCs. However, up-regulation was 
severely impaired when naive CD4+ T cells were co-cultured 
with IL-10–DCs from STAT3 patients (Fig. 3 B). This obser-
vation was confirmed by the cytoplasmic staining of FOXP3 
protein and flow cytometric analysis of the CD4+ T cells   
(Fig. 3 C). This up-regulation of FOXP3 was not likely to be 
mediated by simple T cell activation because naive CD4+  
T cells cultured with control IL-10–DCs proliferated less vig-
orously compared with those with control DCs and because 
naive CD4+ T cells cultured with patient DCs proliferated 
more vigorously compared with those with control DCs in 
the absence or presence of pretreatment with IL-10 (Fig. S4 B). 
iTreg cells from control subjects and STAT3 patients expressed 
equivalent amount of CD25 on their surface, but the expres-
sion levels of CTLA-4 and GITR (glucocorticoid-induced 
TNFR-related) were up-regulated by the co-culture with 
control IL-10–DCs, but the up-regulation was impaired by 
the co-culture with patient IL-10–DCs (Fig. S5).
We  further  evaluated  the  consequences  of  defective 
FOXP3 up-regulation by investigating iTreg cell activity. Puri-
fied CD4+CD25+ T cells from the co-culture were added to 
autologous CD4+CD25 responder T cells, and the mixture 
was stimulated with anti-CD3/CD28 mAbs. CD4+CD25+  
T cells cultured with control IL-10–DCs efficiently suppressed 
the proliferation of CFSE-labeled autologous responder T cells 
(Fig. 3 D, left, second panel). The suppression of proliferation 
was severely impaired by CD4+CD25+ T cells cultured with 
patient IL-10–DCs (Fig. 3 D, left, third panel). We further 
evaluated cytokine production by a co-culture of responder   
T cells and CD4+CD25+ T cells. The production of IFN-, 
IL-5, and IL-13 was suppressed by co-culture with CD4+CD25+ 
cells cultured with control IL-10–DCs (Fig. 3 E). The cyto-
kine  production  was  rather  increased  by  the  addition  of 
CD4+CD25+ T cells cultured with patient IL-10–DCs, which 
might be caused by decreased iTreg cells and increased acti-
vated T cells in this CD4+CD25+ T cell population from 
STAT3 patients. Thus, the IL-10 signaling defect in MoDCs 
results in the impaired generation of tolerogenic DCs and 
iTreg cells.
The generation of FOXP3+ iTreg cells is dependent on 
TGF-1 (Chen et al., 2003; Coombes et al., 2007; Rubtsov 
and Rudensky, 2007; Zheng et al., 2007). We therefore inves-
tigated the relationship between IL-10–DCs and TGF-1 in 
the generation of FOXP3+ iTreg cells. TGF-1 in the culture 
medium efficiently up-regulated FOXP3 expression in naive 
CD4+ T cells in the presence of untreated immature DCs 
(Fig. 3 F). Control IL-10–DCs up-regulated FOXP3 expres-
sion, equivalent to TGF-1 (Fig. 3 F, fifth dataset vs. third   
dataset), and a combination of control IL-10–DCs and TGF-1 
(Fig. 3 F, seventh dataset) further up-regulated FOXP3 ex-
pression. TGF-1 effectively up-regulated FOXP3 expression 
in naive CD4+ T cells when co-cultured with patient DCs, 
but patient IL-10–DCs were inefficient for the up-regulation 
up-regulation of SOCS3 and VCAN (CSPG2), two genes 
responsive to IL-10, was impaired in MoDCs from STAT3 
patients, as demonstrated by comparison with control subjects 
(Fig. 2 A). Intact signal transduction was observed for TGF-1, 
the other critical inhibitory cytokine, in the MoDCs of 
STAT3 patients (Fig. S2 E). We evaluated the effect of prior 
treatment  with  IL-10  on  the  phenotypic  maturation  of 
MoDCs. IL-10 was added to the culture medium on day 3 of 
DC differentiation. The prior treatment with IL-10 did not 
block the differentiation of MoDCs in response to GM-CSF 
and IL-4 (Fig. S3, A and B) but inhibited the LPS-induced 
maturation of MoDCs, with inhibition of the up-regulation 
of co-stimulatory molecules CD80 and CD86 and defective 
up-regulation of the DC maturation marker CD83 in a con-
trol subject. In contrast, the maturation of MoDCs derived 
from STAT3 patients showed little sign of inhibition by prior 
treatment with IL-10 (Fig. S3 C). Up-regulation of CD80, 
CD83, and CD86 expression by LPS was inhibited by IL-10 
pretreatment in control subjects, but the IL-10 pretreatment 
failed to inhibit the up-regulation of CD80, CD83, and CD86 
by LPS in STAT3 patients (Fig. 2 B). Consistent with this ob-
servation, the production of inflammatory cytokines, includ-
ing TNF,  IL-6,  and  IL-12p40,  was  suppressed  by  prior 
treatment with IL-10 in control subjects. The suppression by 
IL-10 was severely impaired in the MoDCs from STAT3 pa-
tients (Fig. 2 C). Untreated and IL-10–treated MoDCs were 
harvested, extensively washed, and co-cultured with third-
party allogeneic naive CD4+ T cells from control subjects. 
LPS-stimulated mature MoDCs induced a significant increase 
in the uptake of [3H]thymidine by naive CD4+ T cells, with 
IL-10–treated  DCs  (IL-10–DCs)  from  a  control  subject 
markedly inhibiting the incorporation of [3H]thymidine.   
In contrast, the down-regulation was very modest in the IL-10–
treated  MoDCs  from  STAT3  patients.  In  the  absence  of 
MoDCs or naive CD4+ T cells, almost no incorporation of 
[3H]thymidine was detected (Fig. S4 A). Production of IFN-, 
IL-5, and IL-13 followed a very similar pattern, with prior 
IL-10 treatment inducing significant down-regulation in control 
subjects and barely detectable down-regulation in STAT3 pa-
tients (Fig. 2 D). Thus, IL-10 was defective in MoDCs from 
STAT3 patients, impairing suppression of (a) the up-regulation 
of co-stimulatory molecules on MoDCs, (b) the up-regulation 
of cytokine production by MoDCs, (c) the proliferation of 
co-cultured naive CD4+ T cells, and (d) cytokine production 
by co-cultured naive CD4+ T cells.
IL-10 signaling defect in MoDCs leads to the defective 
generation of tolerogenic DCs and iTreg cells
Control MoDCs up-regulated the expression of inhibitory 
molecules, including PD-L1, PD-L2, ILT-3, and ILT-4 but 
not ICOS-L by IL-10 treatment. The up-regulation of these 
inhibitory molecules was severely impaired in the MoDCs of 
STAT3 patients (Fig. 3 A). We then investigated the functional 
consequences  of  the  defective  up-regulation  of  inhibitory 
molecules for MoDCs by co-culturing untreated and IL-10–
DCs with third-party allogeneic naive CD4+ T cells from JEM VOL. 208, February 14, 2011 
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Figure 2.  Defective IL-10 signaling in MoDCs from STAT3 patients. (A) Immature DCs from a control subject and a STAT3 patient were stimulated 
with or without IL-10 for 2 h, and the amounts of SOCS3 and VCAN (CSPG2) mRNAs were analyzed by Q-PCR. The representative data are shown at the 
top, normalized to HPRT levels, with the level of unstimulated control cells defined as 1.0. Summary data (n = 8 each) showing fold increase are at the 
bottom. Data are representative of at least two independent experiments performed in triplicate. (B) IL-10–treated MoDCs (IL-10–DCs) were generated 
from CD14+ monocytes by culturing with GM-CSF and IL-4 in the presence of IL-10 from day 3 of the culture. Representative histograms of CD80, CD83, 
and CD86 expression of IL-10–DCs (IL-10) and LPS-matured MoDCs after prior treatment with IL-10 (IL-10 → LPS) from a control subject and a STAT3 
patient are at the top. Dashed lines indicate staining with isotype-matched control mAbs. Summary data (n = 8 each) showing delta values of mean fluo-
rescence intensity (MFI), LPS-matured IL-10–DCs minus IL-10–DCs, of CD80, CD83, and CD86 are at the bottom. (C) Representative cytokine levels in the 
culture supernatants of unstimulated immature MoDCs, LPS-matured MoDCs (LPS), and LPS-matured MoDCs after prior treatment with IL-10 (IL-10 → 
LPS) from a control subject and a STAT3 patient are on the left. Summary data (n = 8 each) showing percent suppression are on the right. All samples 
were evaluated in triplicate. (D) Third-party allogeneic naive CD4+ T cells from control subjects were co-cultured with immature DCs (), LPS-matured 
DCs (LPS), or LPS-matured DCs after prior treatment with IL-10 (IL-10 → LPS), and the levels of the cytokines were evaluated by ELISA in triplicate. Repre-
sentative data are on the left, and summary data of percent suppression by IL-10 pretreatment (n = 8 each) are on the right. Data are representative of at 
least two independent experiments. (A, C, and D) Graphs show mean ± SD. (A–D) Horizontal bars indicate mean values. ***, P < 0.001.
of FOXP3 expression (Fig. 3 F, sixth dataset). Thus, in addition 
to TGF-1, IL-10–DCs play a crucial role in the generation 
of FOXP3+ iTreg cells. Moreover, these results demonstrated 
that the defect in FOXP3 up-regulation was not caused by 
the lack of TGF-1 in IL-10–DCs from STAT3 patients be-
cause the addition of exogenous TGF-1 did not rescue this 240 Impaired iTreg cell genesis in hyper-IgE syndrome | Saito et al.
Figure 3.  IL-10 signaling defect in MoDCs leads to the defective generation of tolerogenic DCs and iTreg cells. (A) Representative histo-
grams showing the levels of PD-L1, PD-L2, ILT-3, ILT-4, and ICOS-L produced by untreated immature MoDCs () and IL-10–DCs (IL-10) from a control 
subject and a STAT3 patient are shown at the top. Dashed lines indicate staining with isotype-matched control mAbs. Summary data showing MFI, JEM VOL. 208, February 14, 2011 
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with a control mAb (Fig. 4 C). The addition of anti–TGF-1 
mAb had no significant effect on the co-culture of naive 
CD4+ T cells with patient IL-10–DCs. Thus, TGF-1 is re-
quired for the formation of FOXP3+ iTreg cells in response to 
control IL-10–DCs.
We also investigated whether DN-STAT3 expression in 
naive CD4+ T cells plays a significant role in the generation of 
iTreg cells by evaluating the up-regulation of FOXP3 mRNA 
levels in naive CD4+ T cells from STAT3 patients. The up-
regulation of FOXP3 mRNA levels in response to IL-10–
DCs from STAT3 patients was impaired, but naive CD4+  
T cells from control subjects and STAT3 patients up-regulated 
FOXP3  mRNA  levels  in  response  to  control  IL-10–DCs   
(Fig. 4 D). Thus, DN-STAT3 expression in MoDCs plays a 
major role in the impairment of FOXP3 mRNA up-regulation, 
and DN-STAT3 expression in T cells plays, at most, a minor 
role in STAT3 patients.
Primary DCs from STAT3 patients are defective in IL-10 
signaling and up-regulation of PD-L1 and ILT-4
We next investigated the development and function of pri-
mary DCs. Two DC subsets were identified in human periph-
eral blood on the basis of the expression of surface molecules, 
including CD11c and CD304 (BDCA-4). Lineage marker 
(Lin) negative HLA-DR+CD11c+CD304 cells are conven-
tional DCs (cDCs), whereas LinHLA-DR+CD11cCD304+ 
cells are plasmacytoid DCs (pDCs). The number of PBMCs 
obtained from the peripheral blood and the percentages of 
cDCs and pDCs were indistinguishable between control sub-
jects and STAT3 patients (Fig. 5 A). We next investigated   
IL-10 signal transduction in primary cDCs and pDCs. The 
transcriptional up-regulation of SOCS3 and VCAN (CSPG2) 
was impaired in both subsets of primary DCs from STAT3 
patients, as demonstrated by comparison with control subjects 
(Fig. 5, B and C). We evaluated the effect of prior treatment 
with IL-10 on the phenotypic maturation of primary cDCs. 
IL-10 was added to the culture 1 d before LPS treatment, 
which inhibited the LPS-induced maturation by inhibiting 
the up-regulation of CD83 and CD86 in control subjects.   
defect to the level of control IL-10–DCs in the presence of 
TGF-1 (Fig. 3 F, eighth dataset vs. seventh dataset). To fur-
ther clarify, we evaluated TGF-1 and IL-10 production from 
MoDCs from control subjects and STAT3 patients (Fig. S6). 
These results indicate that the production of these inhibitory 
cytokines from MoDCs is not impaired in STAT3 patients.
PD-L1, ILT-4, and TGF-1 in response to IL-10–DCs  
and STAT3 in DCs play a major role in FOXP3 up-regulation
A recent study in mice demonstrated that PD-L1 plays an 
important role in inducing FOXP3+ iTreg cells (Keir et al., 
2008; Francisco et al., 2009). We investigated whether defec-
tive PD-L1 expression in IL-10–DCs from STAT3 patients 
played a crucial role in the defective generation of FOXP3+ 
iTreg cells by adding a peptide neutralizing PD-L1 to the co-
culture of IL-10–DCs and naive CD4+ T cells. The addition 
of this PD-L1 peptide significantly decreased the levels of 
FOXP3 mRNA in the naive CD4+ T cells co-cultured with 
control IL-10–DCs (Fig. 4 A). The addition of the neutralizing 
peptide had no detectable effect on co-cultures with MoDCs 
from STAT3 patients.
We next investigated whether defective ILT-4 expression 
in IL-10–DCs from STAT3 patients played an important role 
in the defective generation of FOXP3+ iTreg cells with a neu-
tralizing mAb to the co-culture of IL-10–DCs and naive 
CD4+ T cells. The addition of anti–ILT-4 mAb significantly 
down-regulated the levels of FOXP3 mRNA in the naive 
CD4+ T cells co-cultured with control IL-10–DCs compared 
with a control mAb (Fig. 4 B). The addition of the anti–ILT-4 
mAb had no significant effect on the co-culture of the naive 
CD4+ T cells with patient IL-10–DCs. Thus, in addition to 
PD-L1, ILT-4 up-regulation in response to IL-10 plays an 
important role in the generation of FOXP3+ iTreg cells.
We further investigated the contribution of TGF-1 in 
the up-regulation of FOXP3 by IL-10–DCs because endoge-
nous TGF-1 may be supplied by the DCs or from the cul-
ture medium.  The addition of anti–TGF-1 mAb significantly 
down-regulated the levels of FOXP3 mRNA in the naive 
CD4+ T cells co-cultured with control IL-10–DCs compared 
IL-10–treated minus untreated, of PD-L1, PD-L2, ILT-3, ILT-4, and ICOS-L (n = 8 each) are at the bottom. (B) Q-PCR analysis of FOXP3 mRNA levels 
after the co-culture of third-party allogeneic naive CD4+ T cells from a control subject with untreated immature MoDCs () or IL-10–DCs (IL-10) from 
a control subject and a STAT3 patient. Cultures in the absence of naive CD4+ T cells (DC only) and MoDCs (T only) were used as negative controls. Rep-
resentative data are on the left, and summary data (n = 8 each) showing fold increase are on the right. (C) Flow cytometric analysis of cytoplasmic 
FOXP3 protein levels in naive CD4+ T cells co-cultured with untreated immature MoDCs () and IL-10–DCs (IL-10) from a control subject and a STAT3 
patient. Staining with isotype-matched control mAbs is indicated by dashed lines. Representative data are on the left, and summary data (n = 8 each) 
showing percent increase are on the right. (D) CFSE-labeled CD4+CD25 responder T cells were cultured alone in the absence () or presence of anti-
CD3 and anti-CD28 mAbs or with iTreg cells generated by co-culture with control or STAT3 patient immature DCs (iDCs) or IL-10–DCs. After 5 d, the 
proliferation of CFSE-labeled responder T cells was assessed by flow cytometry. Representative histograms are on the left, and summary data (n = 8 
each) showing the percent increase in nonproliferating cells, numbers in magenta minus numbers in blue, are on the right. (E) Cytokine levels in the 
supernatants of co-cultures of responder T cells and iTreg cells, as indicated. Representative data are on the left, and summary data (n = 8 each) show-
ing percent increase are on the right. Data are representative of at least two independent experiments. (F) Q-PCR analysis of FOXP3 mRNA expression 
after the co-culture of third-party allogeneic naive CD4+ T cells from a control subject with untreated immature MoDCs () or IL-10–DCs from a con-
trol subject and a STAT3 patient in the absence or presence of exogenous TGF-1. We show summary data showing relative  FOXP3 expression (n = 8 
each) performed in triplicate. Data are representative of at least two independent experiments. (B and E) Graphs show mean ± SD. (A–F) Horizontal 
bars indicate mean values. **, P < 0.01; ***, P < 0.001.
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The absolute numbers of cDCs and pDCs in PBMCs were 
similar in the TYK2-deficient patient and a control subject, 
and no significant difference in the differentiation of MoDCs 
was observed on evaluations of forward and side light scatter, 
CD1a expression, and the expression of CD80, CD83, and 
CD86 of DCs before and after LPS-induced maturation   
(Fig. S7, A–D). No inhibition of the up-regulation of CD80, 
CD83, and CD86 by prior treatment with IL-10 was detect-
able in cells from the TYK2-deficient patient (Fig. 6 A).   
The up-regulation of PD-L1, PD-L2, ILT-3, and ILT-4 on 
MoDCs was also defective in the TYK2-deficient patient,   
as shown by comparisons with control subjects (Fig. 6 B).   
An increase in FOXP3 mRNA and protein levels was detect-
able in co-cultures of allogeneic naive CD4+ T cells with con-
trol IL-10-DCs but not in co-cultures with TYK2-deficient 
IL-10–DCs (Fig. 6, C and D). Consistent with these observa-
tions,  no  suppression  of  naive  CD4+ T  cell  proliferation   
and cytokine production (including IFN-, IL-5, and IL-13) 
was detected when TYK2-deficient IL-10–DCs were used 
In contrast, the maturation of primary cDCs derived from 
STAT3 patients was almost intact by prior treatment with   
IL-10 (Fig. 5 D). We did not detect inhibitory effects of IL-10 
on CD80 up-regulation in control subjects and STAT3 pa-
tients. Furthermore, control primary cDCs up-regulated the 
expression of inhibitory molecules, including PD-L1, PD-L2, 
ILT-3 (unpublished data), and ILT-4 by IL-10 treatment. The 
up-regulation  of  these  inhibitory  molecules  was  impaired   
in the primary cDCs of STAT3 patients (Fig. 5 E). These   
results demonstrate that IL-10 signaling is defective not 
only in MoDCs but also in primary DCs, resulting in the   
defective  up-regulation  of  surface  inhibitory  molecules  in 
STAT3 patients.
TYK2-deficient MoDCs are also defective in the generation 
of tolerogenic DCs and iTreg cells
We studied MoDCs from a patient with TYK2 deficiency to 
confirm that the IL-10 signaling defect was responsible for 
the defective generation of tolerogenic DCs and iTreg cells. 
Figure 4.  PD-L1, ILT-4, and TGF-1 in response to IL-10–DCs and STAT3 in DCs play a major role in FOXP3 up-regulation. (A–C) Q-PCR 
analysis of FOXP3 mRNA levels in third-party allogeneic naive CD4+ T cells from control (Cont) subjects co-cultured with untreated immature MoDCs () 
and IL-10–DCs (IL-10) from eight control subjects and eight STAT3 patients. A neutralizing PD-L1 peptide or a control peptide (A), control or ILT-4– 
neutralizing mAb (B), or control or TGF-–neutralizing mAb (C) was added where indicated. (D) Q-PCR analysis of FOXP3 mRNA levels in third-party alloge-
neic naive CD4+ T cells from control subjects and STAT3 patients co-cultured with untreated immature DCs () or IL-10–DCs (IL-10) from control subjects 
and STAT3 patients. Summary data show relative FOXP3  mRNA expression (n = 8 each) and were performed in triplicate. Data are representative of at 
least two independent experiments. (A–D) Horizontal bars indicate mean values. *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 208, February 14, 2011 
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mechanisms are responsible for the allergic manifestations in 
HIES patients. We then investigated DCs, which can regulate 
the immune response and tolerance. IL-10 signal transduction 
was defective in the primary DCs and MoDCs of patients, 
despite the intact TGF-1 signal transduction in these cells. 
This defect resulted in impairment of the suppression of cyto-
kine production and T cell proliferation by IL-10–DCs.   
The generation and suppressive activity of FOXP3+ iTreg cells 
cultured  with  IL-10–DCs  was  impaired  in  HIES  patients.   
The defective generation of tolerogenic DCs and iTreg cells   
in response to IL-10 was also observed in the other type of 
HIES,  TYK2  deficiency. These  results  suggest  that  IL-10   
signaling in DCs may be crucial for the generation of tol-
erogenic DCs and iTreg cells to maintain an appropriate Th1–
Th2–Treg cell balance in HIES patients.
(Fig. 6, E and F). MoDCs from the TYK2-deficient patient pro-
duced an equivalent amount of TGF-1 and reduced amount   
of IL-10 compared with a control subject, which might be 
associated with the fact that the type I IFN signal is impaired in 
the TYK2-deficient patient but not in STAT3 patients.(Fig. S7, 
E and F). Thus, the IL-10 signaling defect in HIES patients, 
STAT3 patients, and the TYK2-deficient patient results in the 
impaired generation of tolerogenic DCs and iTreg cells.
DISCUSSION
We found that the Th1 and Th2 differentiation of naive CD4+ 
T cells and the suppressive activity of Treg cells were normal   
in STAT3 patients. Recent data have shown that Ig isotype 
switching in B cells is normal in STAT3 patients (Avery et al., 
2010). Thus, it is not likely that T cell– and B cell–intrinsic 
Figure 5.  Primary DCs are defective in IL-10 signal and up-regulation of PD-L1 and ILT-4. (A) Dot blots are gated on Lin-negative HLA-DR–
positive cells from a control subject and a STAT3 patient. cDCs are CD11c+CD304 (BDCA-4), and pDCs are CD11cCD304+. Representative dot plots from 
a control subject and a STAT3 patient are shown at the top, and pooled data (n = 8 each) showing percentages of cDCs and pDCs are at the bottom.  
(B and C) Primary cDCs (B) and pDCs (C) from a control subject and a STAT3 patient were stimulated with IL-10 for 2 h, and the amounts of SOCS3 and 
VCAN (CSPG2) mRNAs were analyzed by Q-PCR. Representative data are shown at the top, normalized to HPRT levels, with the level of unstimulated con-
trol cells defined as 1.0. Summary data (n = 8 each) showing fold increase are at the bottom. Data are representative of at least two independent experi-
ments performed in triplicate. Graphs show mean ± SD. (D) Representative histograms of CD80, CD83, and CD86 expression on control and STAT3 cDCs 
stimulated with LPS alone or LPS after IL-10 treatment. Dashed lines indicate staining with isotype-matched control mAbs. Summary data showing MFI, 
LPS stimulated minus LPS-stimulated IL-10–DCs, (n = 8 each) are at the bottom. (E) Representative histograms of PD-L1, PD-L2, and ILT-4 expression of 
primary cDCs () and IL-10–treated (IL-10) primary cDCs from a control subject and a STAT3 patient are shown at the top. Summary data (n = 8 each) 
showing MFI, IL-10 treated minus untreated, of PD-L1, PD-L2, and ILT-4 are shown at the bottom. Data are representative of at least two independent 
experiments. (A–E) Horizontal bars indicate mean values. **, P < 0.01; ***, P < 0.001.244 Impaired iTreg cell genesis in hyper-IgE syndrome | Saito et al.
HIES patients. In humans, we are not certain 
about the nTreg cell/iTreg cell ratio in the pe-
ripheral  blood  under  resting  conditions.  Our 
data suggest that most of the Treg cells in the pe-
ripheral blood are nTreg cells, which are derived 
from the thymus and are independent of the 
IL-10 signal. iTreg cells in the peripheral blood 
may be a minor population under resting con-
ditions but may play a crucial role in the regula-
tion of antigen-specific allergic reactions.
Human  peripheral  blood  Treg  cells  sup-
pressed proliferation and Th2 cytokine pro-
duction by responder T cells stimulated with 
allergens (Bellinghausen et al., 2003; Grindebacke et al., 2004; 
Ling et al., 2004). CD4+ T cells cultured with IL-10–DCs 
have antigen-specific iTreg cell activity (Steinbrink et al., 
2002). In vitro experiments suggested that the suppression is 
dependent on cell to cell contact between iTreg cells and re-
sponder T cells and is not mediated by soluble factors. In this 
study, we found that the generation of FOXP3+ iTreg cells by 
The exposure of the skin to allergens induces allergen-
specific unresponsiveness, possibly because of the production 
of IL-10 by keratinocytes (Enk and Katz, 1992; Enk et al., 
1993). Langerhans cells and dermal DCs receive IL-10 signal 
and induce allergen-specific tolerance. This defect in IL-10–
mediated tolerance to innocuous environmental antigens may 
be one of the mechanisms underlying the allergic signs in 
Figure 6.  TYK2-deficient MoDCs display defective 
generation of tolerogenic DCs and iTreg cells. (A) Flow 
cytometric analysis of the CD80, CD83, and CD86 expres-
sion on IL-10–DCs (IL-10) and LPS-matured MoDCs after 
prior treatment with IL-10 (IL-10 → LPS), with cells ob-
tained from a control subject and a patient with TYK2 
deficiency. We show representative histograms from 
three independent experiments. (B) Flow cytometric analy-
sis of the levels of PD-L1, PD-L2, ILT-3, and ILT-4 in un-
treated immature MoDCs () and IL-10–DCs (IL-10) from 
a control subject and a TYK2 deficiency. We show repre-
sentative histograms from three independent experi-
ments. (C) Q-PCR analysis of FOXP3 mRNA levels after 
the co-culture of third-party allogeneic naive CD4+  
T cells from a control subject with untreated immature 
MoDCs () or IL-10–DCs (IL-10) from a control subject 
and a TYK2-deficient patient. We show representative 
data from three independent experiments. (D) Flow cyto-
metric analysis of cytoplasmic FOXP3 protein levels in 
untreated immature MoDCs () and IL-10–DCs (IL-10) 
from a control subject and a TYK2-deficient patient.  
Isotype-matched control (isotype) antibody staining is 
indicated by a dashed line. We show representative  
histograms from three independent experiments.  
(E) Third-party allogeneic naive CD4+ T cells from control 
subjects were co-cultured with immature MoDCs (), 
LPS-matured MoDCs (LPS), or LPS-matured MoDCs after 
prior treatment with IL-10 (IL-10 → LPS). The cells were 
obtained from a control subject and a TYK2-deficient 
patient. After 5 d, proliferation was evaluated by pulsing 
the cells with 1 µCi (37 kBq) [3H]thymidine for the final 
18 h of culture. All samples were evaluated in triplicate. 
We show representative data from three independent 
experiments. (F) Cells were cultured as in E, and cytokine 
levels were evaluated as indicated. All samples were eval-
uated in triplicate. We show representative data from at 
least three independent experiments. (C, E, and F) Graphs 
show mean ± SD. *, P < 0.05; **, P < 0.01.JEM VOL. 208, February 14, 2011 
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nonatopic healthy individuals (Taams et al., 2002; Ling et al., 
2004). However, patients with atopic dermatitis have normal 
numbers of Treg cells in the periphery with normal suppressive 
activity (Ou et al., 2004). These results suggest that iTreg cells 
may be more important than nTreg cells in controlling atopic 
dermatitis. Consistent with this hypothesis, a recent study using 
two mouse strains, one capable of generating iTreg cells but inca-
pable of generating nTreg cells and the other unable to generate 
either iTreg or nTreg cells, suggested that iTreg cells controlled al-
lergic inflammation against innocuous environmental allergens, 
whereas nTreg cells did not (Curotto de Lafaille et al., 2008).
TGF-1 is the other crucial inhibitory cytokine regulat-
ing lymphocyte homeostasis, inhibiting Th1 and Th2 cell re-
sponses and promoting the differentiation of iTreg cells (Li   
et al., 2006). One previous study suggested that STAT3 might 
be involved in transduction of the TGF-1 signal (Ohkawara 
et al., 2004), but we detected no impairment of TGF-1   
signaling  in  DCs  from  STAT3  patients.  Unexpectedly,  we 
found that TGF-1 and IL-10–DCs operated synergistically 
to up-regulate FOXP3 expression in naive CD4+ T cells. This 
suggests  that  the  defective  generation  of  IL-10–DCs  may 
have a far-reaching impact on the induction of iTreg cells in 
HIES patients.
We provide in this study the first demonstration that an 
IL-10 signaling defect leads to the impairment of tolerogenic 
DC and iTreg cell production in the HIES. These results sug-
gest that the defect in tolerogenic DC and iTreg cell produc-
tion, even in the presence of normal nTreg cells, may contribute 
to the development of complex clinical manifestations, in-
cluding allergic inflammation in HIES patients. Furthermore, 
a unique combination of defective Th17 differentiation and 
iTreg cell generation may culminate in the development of 
atopic dermatitis but not enterocolitis in HIES patients.
MATERIALS AND METHODS
Patients. All STAT3 patients enrolled in this study had typical clinical find-
ings associated with HIES and a National Institutes of Health score >40 
points (Table I; Grimbacher et al., 1999). The diagnosis was confirmed by the 
identification of mutations in the STAT3 gene. The patient with TYK2 defi-
ciency has been described elsewhere (Minegishi et al., 2006). The study was 
approved by the Tokyo Medical and Dental University Ethics Committee, 
and written informed consent was obtained from all patients. Control indi-
viduals were nonatopic, age-matched, and equivalent in sex distribution to 
HIES patients. All of the patients and control subjects were in a healthy state 
when their blood samples were collected.
Antibodies,  cytokines,  and  peptides. We used mAbs against CD4   
(RPA-T4), CD14 (M5E2), CD11c (B-ly6), CD123 (9F5), HLA-DR (TU36), 
CD25 (M-A251), CD62L (Dreg 56), CD1a, (HI149), CD80 (L307.4), CD86 
(2331), CD83 (HB15e), PD-L1 (MIH1), PD-L2 (MIH18), FOXP3 (259D/C7), 
and CTLA-4 (CD152; BNI3), a Lin cocktail (antibodies against CD3   
[SK7], CD14 [MP9], CD16 [3G8], CD19 [SJ25C1], CD20 [L27], and 
CD56 [NCAM16.2]), and mAbs against IFN- (4S.B3) and IL-4 (8D4-8), 
neutralizing mAbs against IFN- (B27), IL-4 (MP4-25D2), and isotype-
matched control mAbs, all of which were purchased from BD. We obtained 
antibodies against ILT-3 (CD85K; 293623), ILT-4 (CD85d; 287219), LAP 
(latency-associated  peptide;  TGF-1;  27235),  and  GITR  (TNFRSF18; 
110416) from R&D Systems. Anti–ICOS-L antibody (MIH12) was obtained 
from eBioscience. Anti-CD304 (BDCA-4) antibody (AD5-17F6) was obtained 
IL-10–DCs was impaired in HIES patients. Evidence is accu-
mulating  to  suggest  that  interactions  between  tolerogenic 
DCs and Treg cells play an important role in the maintenance 
of immune tolerance against self-antigens and innocuous en-
vironmental antigens (Yamazaki et al., 2006a; Hubert et al., 
2007). CD4+CD25+ Treg cell populations can expand in the 
presence of DCs with intact suppressive activity in vitro and 
in vivo (Yamazaki et al., 2006b). In addition to the IL-10 sig-
nal provided by the cells sensing innocuous environmental 
antigens, the IL-10–mediated positive feedback loop between 
tolerogenic DCs and iTreg cells is probably impaired in HIES 
patients, and this may also constitute one of the mechanisms 
underlying the atopic signs in HIES patients.
A large number of clinical studies have demonstrated that 
IL-10 is involved in the molecular pathogenesis of atopic dis-
orders in humans. The frequency of allergen-specific, IL-10–
secreting  T cells is significantly higher in nonatopic individuals 
than in atopic patients (Akdis et al., 2004). IL-10 levels are in-
versely correlated with the severity of human allergic diseases 
(Borish et al., 1996; Lim et al., 1998). Furthermore, allergen-
specific immunotherapies increase IL-10 synthesis by T cells 
(Francis et al., 2003; Vissers et al., 2004). All of these findings 
suggest that IL-10 plays a key role in the control of atopic 
diseases in humans.
In contrast, mice lacking IL-10 or the IL-10 receptor de-
velop spontaneous inflammation in the large intestine (Kühn 
et al., 1993; Davidson et al., 1996; Spencer et al., 1998). Mice 
with a Treg cell–specific IL-10 deficiency also display inflam-
mation of surfaces in contact with the environment such as 
the colon, lungs, and skin (Rubtsov et al., 2008). In humans, 
mutations in the genes encoding IL-10 receptor subunits have 
been found in patients with early-onset enterocolitis (Glocker 
et al., 2009). Thus, a lack of IL-10 signaling results in entero-
colitis in both humans and mice. Interestingly, in patients with 
HIES, immune responses to innocuous environmental anti-
gens are limited to the skin, with no marked increase in the 
frequency of enterocolitis. One possible reason for this dis-
crepancy is the existence of a partial, as opposed to complete, 
IL-10 signaling deficiency in STAT3 patients, creating a situ-
ation resembling Treg cell–specific IL-10 deficiency. An alter-
native nonmutually exclusive explanation is that, in addition 
to the IL-10 signaling defect, STAT3 patients have defective 
Th17 cell development (de Beaucoudrey et al., 2008; Ma   
et al., 2008; Milner et al., 2008; Renner et al., 2008; Minegishi 
et al., 2009). The combination of Th17 cell deficiency and 
IL-10 signaling may result in allergic signs but prevent the 
development of enterocolitis (Brand, 2009).
Treg cells mediate peripheral tolerance and play a central 
role  in  determining  several  immunopathologies,  including 
autoimmunity, chronic infections, tumor development, and 
allergies (Hawrylowicz and O’Garra, 2005). FOXP3+ Treg cells 
are involved in protecting humans against allergic diseases, as 
patients with IPEX syndrome suffer from allergic symptoms 
(Bennett et al., 2001; Wildin et al., 2001). PBMCs from atopic 
patients proliferate more extensively and produce more Th2 
cytokines in response to allergens than do PBMCs from   246 Impaired iTreg cell genesis in hyper-IgE syndrome | Saito et al.
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CD4+CD25 responder T cells in 96-well round-bottomed plates con-
taining a 1:100 (vol/vol) dilution of anti-CD3/CD28 mAb beads. After 5 d, 
the proliferation of the CFSE-labeled CD4+CD25 T cells was assessed by 
flow cytometry.
Flow  cytometric  analysis. Cells were analyzed on a FACSCalibur or 
FACSCanto II machine (BD) using CellQuest or FACSDiva software (BD).
Mannose  receptor–mediated  endocytosis.  1  mg/ml  FITC–dextran 
(Sigma-Aldrich) was incubated with 105 cells at 37°C or 4°C for 2 h. FITC-
dextran uptake was stopped by adding ice-cold PBS, and the cells were then 
thoroughly washed in a refrigerated centrifuge. Samples were then subjected 
to flow cytometry. The level of antigen uptake by DCs was assessed as the differ-
ence between the test (37°C) and control (4°C) values for each sample.
Cytokine ELISA. For cytokine determinations, the culture supernatant was 
stored at 80°C until use, and the amounts of IFN-, TNF, IL-5, IL-6, IL-10, 
IL-12p40, and IL-13 present were then determined by ELISA, according to 
the kit manufacturer’s instructions (BD).
Intracellular staining. Naive CD4+ T cells were cultured with plate-bound 
antibodies against CD3 and CD28 in Th1 conditions, IFN- plus antibody 
against IL-4 in Th2 conditions, or IL-4 and antibody against IFN-, and the 
cells were then fixed and permeabilized (Cytofix/Cytoperm reagents; BD) 
and stained with mAbs against CD4, IFN-, and IL-4, according to the man-
ufacturer’s instructions (BD). CTLA-4 staining was performed after Cytofix/
Cytoperm treatment.
FOXP3 intracellular staining. Naive CD4+ T cells co-cultured with un-
treated DCs or IL-10–DCs were fixed and permeabilized with the human 
FOXP3 buffer set (BD) and stained with mAb against FOXP3.
RNA isolation and real-time quantitative RT-PCR (Q-PCR). Cells 
were harvested for total RNA isolation with the Fastpure RNA kit (Takara 
Bio Inc.). Total RNA was reverse transcribed with Primescript RT (Takara 
Bio Inc.). An aliquot of the RT products was used as a template for real-time 
PCR with SYBR green Mastermix (Takara Bio Inc.) on an Mx3005P ther-
mocycler (Agilent Technologies) with SYBR green I dye as the amplicon 
detector and ROX as the passive reference. The gene for HPRT (hypoxan-
thine phosphoribosyltransferase) was amplified as an endogenous reference. 
Quantification was achieved by both the standard curve and comparative 
CT methods.
Data analysis. Data are expressed as means ± the SD. Unpaired t tests or 
analysis of variance was used for statistical analysis. P-values <0.05 were con-
sidered significant (*, P < 0.05; **, P < 0.01; and ***, P < 0.001).
Online supplemental material. Fig. S1 shows normal Th1 and Th2 dif-
ferentiation from naive CD4+ T cells but increased Th2 cytokine production 
from activated T cells in PBMCs of STAT3 patients. Fig. S2 shows that 
MoDC differentiation in vitro and TGF-1 signaling in MoDCs are intact in 
STAT3 patients. Fig. S3 shows that IL-10 treatment does not impair the dif-
ferentiation of MoDCs, but down-regulation of CD80, CD83, and CD86 is 
defective in MoDCs from STAT3 patients. Fig. S4 shows that suppression of 
proliferation by IL-10 pretreatment is impaired in MoDCs from STAT3 pa-
tients. Fig. S5 shows that up-regulation of FOXP3, CTLA-4, and GITR is 
impaired in iTreg cells co-cultured with patient IL-10–DCs. Fig. S6 shows   
that MoDCs from STAT3 patients produce equivalent amounts of TGF-1. 
Fig. S7 shows the characterization of primary DCs and MoDCs from the   
patient with TYK2 deficiency. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20100799/DC1.
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from Miltenyi Biotec. Recombinant human (rh) GM-CSF, IL-4, IFN-,   
IL-10, and TGF-1 were purchased from PeproTech. Neutralizing PD-L1 
peptide was obtained from Abcam, and an irrelevant peptide was used as a 
negative control.
PBMCs and naive CD4+ T cell culture. PBMCs were isolated by Ficoll 
density gradient centrifugation (Histopaque-1077; Sigma-Aldrich). PBMCs 
were cultured in 96-well plates in RPMI 1640 medium supplemented with 
10% fetal bovine serum, 200 mM l-glutamine, 100 mM sodium pyruvate, 
nonessential amino acids, minimal essential medium vitamins (all from Invit-
rogen), 50 U/50 µg/ml penicillin/streptomycin (Nacalai Tesque), and 50 µM 
mercaptoethanol. Cultures were stimulated with a 1:100 (vol/vol) dilution of 
anti-CD3/CD28  mAb–coated  beads  from  Invitrogen.  For  some  experi-
ments, the following mAbs and cytokines were added: 10 ng/ml rhIFN-,   
10 ng/ml rhIL-4, and neutralizing antibodies against 10 µg/ml IFN- and   
10 µg/ml IL-4.
Treg cell purification and functional assay. Total CD4+ T cells were   
isolated with the CD4+ T cell isolation kit (BD). The cells were stained for 
sorting with antibodies against CD4, CD25, and CD62L. All mAbs were 
used after dialysis to remove sodium azide (Baecher-Allan et al., 2006). 
CD4+CD25CD62Lhi responder T cells and CD4+CD25+CD62Lhi Treg cell 
populations were isolated by sorting with a cell sorter (Moflo; Beckman 
Coulter). In the postsort analysis, the resulting cell preparation was found to 
be to >99% purity. Co-culture was set up as follows: 1.25 × 104 responder   
T cells and 1.25 × 103 Treg cells were co-cultured for 5 d with a 1:100 (vol/vol) 
dilution of magnetic beads coated with antibodies against CD3/CD28.   
Responder T cells were used as a negative control. Proliferation was assessed 
by adding 1 µCi (37 kBq) [3H]thymidine (methyl-[3H]thymidine; ICN Bio-
medicals) to the culture medium for the final 18 h.
Isolation of primary DCs. Primary DCs were obtained by the enrich-
ment using a human DC enrichment set (BD) and cell sorting with FACS 
Aria II (BD): cDCs as LinHLA-DR+ CD11c+CD304 cells and pDCs as 
LinHLA-DR+CD11cCD304+ cells. In the postsort analysis, the resulting 
cell preparation was to >99% purity.
In vitro generation of MoDCs. CD14+ monocytes were isolated from 
PBMCs with immunomagnetic beads (BD) at a purity of >98%. Monocytes 
were cultured in the presence of 50 ng/ml GM-CSF and 10 ng/ml IL-4 for 
5 d. For differentiation into mature DCs, immature DCs were stimulated on 
day 5 with 100 ng/ml LPS (O55:B5; Sigma-Aldrich). For the generation of 
tolerogenic DCs, 100 ng/ml IL-10 was added to the culture on day 3. Non-
adherent DCs on day 7 were used for T cell stimulation.
Allogeneic naive CD4+ T cell proliferation assay. Naive CD4+ T cells 
were  negatively  selected  from  PBMCs  through  the  depletion  of  CD8, 
CD11b, CD16, CD19, CD36, CD41a, CD45RO, CD56, CD123, -TCR, 
and glycophorin A–positive cells, with antibody-coated paramagnetic micro-
beads (naive CD4+ T cell isolation kit from BD), according to the manufac-
turer’s protocol. The purity of the naive CD4+ T cell preparation exceeded 
95%. For proliferation assays, 105 naive CD4+ T cells were co-cultured in   
96-well round-bottomed plates, in triplicate, with 104 allogeneic DCs. After   
5 d, the cells were pulsed with 1 µCi (37 kBq) per well of [3H]thymidine   
for 18 h, and [3H]thymidine incorporation was evaluated with a  counter 
(model 1450; PerkinElmer).
iTreg cell preparation and functional evaluation. Naive CD4+ T cells 
were obtained from PBMCs with the naive CD4+ T cell isolation kit. We ob-
tained CD4+CD25 responder T cells by depleting the CD25+ cells with 
magnetic beads coated with an antibody against CD25 (BD). The resulting 
cell preparation was >95% pure. We obtained iTreg cells by setting up co- 
cultures as described for the Allogeneic naive CD4+ T cell proliferation assay 
and purifying CD4+CD25+ cells after 3 d with immunomagnetic beads. 
CD4+CD25+ iTreg cells were co-cultured with CFSE-labeled autologous 248 Impaired iTreg cell genesis in hyper-IgE syndrome | Saito et al.
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